Allianz Asset Management GmbH Increases Stock Position in Insulet Corporation $PODD

Key Points

• Allianz Asset Management GmbH significantly increased its investment in Insulet Corporation by 89.1%, acquiring a total of 262,878 shares valued at approximately $82.59 million as of the latest SEC filing.
• Multiple hedge funds have shown renewed interest in Insulet, with American Century Companies Inc. and Kayne Anderson Rudnick Investment Management LLC dramatically increasing their stakes in the company.
• Insulet's recent earnings report exceeded expectations, with a 32.9% increase in revenue year-over-year and earnings per share of $1.17, surpassing the expected $0.92.

Allianz Asset Management GmbH increased its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 89.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 262,878 shares of the medical instruments supplier's stock after buying an additional 123,862 shares during the period. Allianz Asset Management GmbH owned 0.37% of Insulet worth $82,591,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. American Century Companies Inc. grew its position in shares of Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after purchasing an additional 297,734 shares during the period. Nuveen LLC acquired a new stake in shares of Insulet in the first quarter valued at about $74,163,000. Kayne Anderson Rudnick Investment Management LLC grew its position in shares of Insulet by 1,316.5% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier's stock valued at $50,818,000 after purchasing an additional 179,850 shares during the period. Vanguard Group Inc. grew its position in shares of Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the period. Finally, Federated Hermes Inc. grew its position in shares of Insulet by 23.4% in the first quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier's stock valued at $166,198,000 after purchasing an additional 120,197 shares during the period.

Insider Activity

In related news, SVP Prem Singh sold 687 shares of the firm's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on PODD shares. Rothschild & Co Redburn lifted their target price on shares of Insulet from $350.00 to $370.00 and gave the company a "buy" rating in a research report on Friday, October 3rd. Jefferies Financial Group reiterated a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Zacks Research raised shares of Insulet from a "hold" rating to a "strong-buy" rating in a research note on Tuesday. Wells Fargo & Company raised their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Finally, Morgan Stanley reissued an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $348.05.

Insulet Price Performance

Insulet stock opened at $316.29 on Friday. Insulet Corporation has a 12-month low of $226.50 and a 12-month high of $353.50. The stock has a market cap of $22.26 billion, a P/E ratio of 96.14, a PEG ratio of 2.61 and a beta of 1.40. The company has a 50-day moving average price of $325.99 and a 200 day moving average price of $301.60. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same period last year, the business earned $0.55 earnings per share. Insulet's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.